ReviewAnnals of nuclear medicine2024
Recent topics in fibroblast activation protein inhibitor-PET/CT: clinical and pharmacological aspects.
Review in Annals of nuclear medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- Diagnostic efficacy of [European journal of nuclear medicine and molecular imaging · 2024Trial
- Research progress and trends on PET/CT imaging of pancreatic cancer: a bibliometric analysis.Discover oncology · 2026Article
- Targeting cancer-associated fibroblasts for real-time intraoperative tumor identification with a spray-on fluorescent probe.Science advances · 2025Article
- Far-Red Spray-On Imaging Probes for FAP-Targeted Cancer Surgery.Bioconjugate chemistry · 2025Article
- Cardiovascular imaging in cardio-oncology.Japanese journal of radiology · 2024Review
- Recent advancements in new tracers from first-in-human studies.Annals of nuclear medicine · 2024Review
- [Frontiers in oncology · 2024Article
- Fibroblast activation protein is a cellular marker of fibrotic activity in canine idiopathic pulmonary fibrosis.Frontiers in veterinary science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, positron emission tomography (PET) with fibroblast activation protein inhibitor (FAPI) has gained significant attention as an advanced tumor diagnostic imaging tool. FAPI PET has a promising potential owing to its ability to accurately depict most malignant tumors. It has an accuracy that is comparable to or surpassing the diagnostic accuracy of PET using
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.